research use only

Metronidazole Antineoplastic and Immunosuppressive Antibiotics inhibitor

Name: Metronidazole
Brand: Selleck Chemicals
SKU: S1907
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S1907

Metronidazole, a synthetic antibacterial and antiprotozoal agent of the nitroimidazole class, is used against protozoa.

Chemical Structure

Molecular Weight: 171.15

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.97%

99.97

Related Targets	DNA/RNA Synthesis HDAC Topoisomerase PPAR PARP Sirtuin ATM/ATR Casein Kinase eIF MDM2/MDMX DNA-PK DHFR Nucleoside Analog/Antimetabolite DNA alkylator Telomerase Thymidylate Synthase CRISPR/Cas9 RAD51 BMI-1 LIM kinase RNR Alkylating Agent NUDIX High-mobility Group OGG1 MTH1 G-quadruplex SMN FENs WRN
Related Products	Puromycin Dihydrochloride Staurosporine (STS) Cyclosporin A Oligomycin A (MCH 32) Geldanamycin Honokiol Streptozotocin (STZ) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III Pirarubicin Hygromycin B Embelin Roxithromycin Kasugamycin hydrochloride Fumagillin Nigericin sodium salt Fusidate Sodium Dimetridazole

Chemical Information, Storage & Stability

Molecular Weight	171.15	Formula	C₆H₉N₃O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	443-48-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC1=NC=C(N1CCO)[N+](=O)[O-]

Solubility

In vitro
Batch:

DMSO : 34 mg/mL (198.65 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 12 mg/mL (Warmed with 50℃ water bath; Ultrasonicated)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.7mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 34 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.24mg/ml (1.40mM)	Taking the 1 mL working solution as an example, add 50 μL of 4.8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	DNA synthesis ^[1]
In vitro	Metronidazole is relatively inactive until it is metabolized within host or microbial cells. It is activated when it receives an electron from ferredoxin or flavodoxin that is reduced by POR in anaerobic or microaerophilic bacteria or luminal parasites. This compound damages cells by forming protein and DNA adducts. ^[1] It has activity against protozoans like Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis, for which the drug is first approved as an effective treatment. The activity of this chemical against anaerobic bowel flora has been used for prophylaxis and treatment of patients with Crohn's disease who might develop an infectious complication. It has played an important role in anaerobic-related infections. This compound has notable effectiveness in treating anaerobic brain abscesses. ^[2] Its resistance tends to result from de novo mutation in the resident rdxA gene, rather than from lateral transfer of mutant rdxA (or other) genes from unrelated but Mtzr strains. It partially inhibits growth stimulate forward mutation to rifampin resistance in rdxA(+) (Metronidazole(s)) and also in rdxA (Metronidazole(r)) H. pylori strains, and that expression of rdxA in Escherichia coli results in equivalent Mtz-induced mutation. ^[3] This compound leads to apoptosis-like features in growing cultures of axenic B. hominis, including key morphological and biochemical features of programmed cell death (PCD), viz. nuclear condensation and nicked DNA in nucleus, reduced cytoplasmic volume, externalization of phosphatidylserine and maintenance of plasma membrane integrity with increasing permeability. ^[4]
References	[1] https://pubmed.ncbi.nlm.nih.gov/10390199/ [2] https://pubmed.ncbi.nlm.nih.gov/1720382/ [3] https://pubmed.ncbi.nlm.nih.gov/10960092/ [4] http://www.ncbi.nlm.nih.gov/pubmed/ 14702395

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06387147	Not yet recruiting	Acute Mesenteric Ischemia	Assistance Publique - Hôpitaux de Paris	September 1 2024	Phase 3
NCT05748145	Recruiting	Colorectal Cancer	Oncology Institute of Southern Switzerland	September 11 2023	Phase 2
NCT04273997	Unknown status	Pilonidal Sinus	S.L.A. Pharma AG	October 1 2021	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):